Imeik Technology Development Co., Ltd. Overview
Pro stress-test →Imeik Technology Development engages in research and development, production, and transformation of biomedical soft tissue repair materials in China. The company is a publicly traded medical aesthetics and biomedical materials specialist with a market cap of approximately 43.95 billion yuan listed on the Shenzhen Stock Exchange.
Strategic Profile
Pro stress-test →The company offers aesthetic medicine products including cross-linked sodium hyaluronate gel formulations, poly facial implant thread, and various injection solutions alongside skincare products. Recent financial data shows the company facing near-term headwinds, with Q1 2025 revenue of 0.663 billion yuan down 17.90% year-on-year, though Imeik's most recent strategic initiative includes a merger/acquisition with REGEN Biotech positioning for international expansion.
Competitive Landscape
Pro stress-test →Imeik competes in China's medical aesthetics and biomedical materials sector against other domestic players and international competitors like Allergan (Botox) and Sinclair Pharma. The company differentiates through proprietary hyaluronate formulations and vertical integration, though it faces pricing pressure from commoditization and new entrants in the growing Chinese market.
Industry Context
Imeik Technology Development Co., Ltd. operates in Medical Aesthetics & Biomedical Materials.
Key facts
Founded: 2004 · Headquarters: Beijing, China · Employees: 1,223 · Revenue: 2.87B CNY (2023) · Market cap: 43.95B CNY